| Background: Primary bronchial lung cancer, lung cancer for short, is a common malignant tumor in chest, is also one of the leading causes of cancer death in the human. Both men and women, the incidence of lung cancer in recent years, and the mortality of lung cancer is rising year by year, the lung cancer mortality rate is higher than all other cancer mortality. But early symptoms of lung cancer is not easy to show, At the same time, due to early detection rate is relatively low, most of the patients in the clinical diagnosis has been in the advanced stage of disease. About more than 75% of the patients with confirmed has been locally advanced or metastatic tumor, and only about 5% of patients can survive more than 5 years after diagnosis. With the rapid development in the field of tumor molecular biology, Many people in the research of tumor gene expression and the relationship between tumor found that during the occurrence and development of lung cancer is associated with a higher incidence of cancer gene to make some changes. Visible genetic changes in the occurrence of malignant tumor development plays a decisive role. p16 in chromosome 9 p21 area, its coding in selecting and inhibition of CDK4 proteins can be specific, the negative regulation of cell proliferation. After the p16 gene inactivation is unable to make it express the protein and the combination of CDK4-Cyclin D, unlimited access to the G1 / S phase cells, eventually lead to cancer. p16-CDK4/6-Cyclin Dl-p Rb pathway is an important cell cycle in the cell cycle, in this pathway pl6 gene inactivation and the occurrence of lung cancer are closely linked. Therefore, p16 gene in terms of targeted therapy, can be used as a molecular target of new research directions.Due to the smaller molecular weight of p16 gene for gene diagnosis and treatment process, more convenient, more easy to operate, and interact with other cancer genes, can play a better synergy, are enhanced tumor suppressor role, make its can be used in the treatment of cancer target. This study through the detection of p16 protein in non-small cell lung cancer tissue in the positive expression rate, for the early diagnosis of lung cancer in clinical provides certain theoretical basis, as well as to the potential of targeted drugs have provided the certain basis.Objective: To detect the p16 protein expression in non-small cell lung cancer tissues and explore p16 protein expression level and the correlation of non-small cell lung cancer, certain clinical characteristics.Method: Collection of yanan university affiliated hospital in 2008 ~ 2013, 63 cases of lung cancer patients as experimental group, which was confirmed by pathology, 39 cases of men, women, 24 cases, 38 to 71 years old, with an average age of 53. Squamous carcinoma in 36 cases, 27 cases of adenocarcinoma. With AJCC seventh edition as a standard TNM stage, stage I in 22 cases of stage II in 19 cases, 22 cases of phase III. High, low differentiation in 40 cases, 23 differentiation; With lymph node metastasis in 36 cases, 27 cases with no lymph node metastasis. Alternate 26 patients with lung benign lesions as the control group, 15 cases of men and women in 11 cases, ages 24 to 72 years old, 9 cases of bronchiectasis and pneumonia false tumor in 5 cases, 12 cases of TB.All specimens after materials using 10% formalin fixed, paraffin embedding. The streptomycin resistance- biotin peroxidase immunohistochemical method(SP method) to detect pathology confirmed 63 cases of non-small cell lung cancer patients and 26 cases of lung in the expression of p16 protein in patients with benign lesions.Result: Lung cancer positive expression rate of p16 protein was significantly lower than pulmonary benign lesions(47.62% vs 100%,χ2= 21.644, p < 0.05); Adenocarcinoma of p16 protein positive expression rate was significantly higher than squamous cell carcinomas(77.78% vs 25.00%,χ2= 17.230, p < 0.05); I ~ II phase of p16 protein positive expression rate of lung cancer is significantly higher than stage III lung cancer(58.54% vs 27.27%,χ2= 5.610, p < 0.05); No lymph node metastasis p16 protein positive expression rate of lung cancer with lymph node metastasis of lung cancer is significantly higher than(68.97% vs 29.41%,χ2= 9.817, p < 0.05); Is high, the differentiation of lung cancer in the positive expression rate of p16 protein is higher than low differentiation of lung cancer(55.00% vs 34.78%,χ2=2.393, p > 0.05); P16 protein in patients with male and female respectively in the positive expression rate(41.03% vs 58.33%,χ2= 1.784, p > 0.05); In the < 50 years old with 50 or more p16 protein in patients with positive expression rate respectively(50.00% vs 45.45%,χ2 = 0.130, p > 0.05).Conclusion: p16 protein expression in patients with lung cancer group were significantly reduced. Low p16 protein expression and lung squamous carcinoma, late stages, lymph node metastasis was significantly positive correlation. |
PDF Full Text Request